Nice | Tolvaptan for treating autosomal polycystic kidney disease

15th February 2016 by Louise Hudman

Nice | Tolvaptan for treating autosomal polycystic kidney disease

This is a new guideline from NICE advising that tolvaptan can be used for treating autosomal polycystic kidney disease. It is a selective vasopressin antagonist which can reduce cell proliferation, cyst formation and fluid excretion. This reduces kidney growth and protects renal function.

Patients need to have:

  • CKD 2 or 3
  • Rapidly progressing disease

It has several side-effects, including polyuria, nocturia and frequency of urination. It can also be hepatotoxic and can elevate liver function tests.

MIMS Learning | Chronic kidney disease: clinical review

Read for free

Sign up to access everything.

Three-month free trial


Already a member? Login to view this content.


"I've tried simple templates or hard copies of locum packs before but find they so quickly become out of date. I like the way the NASGP's Standardised Practice Information Portal is easier to navigate and update than these paper-based systems."

Dr Amy Kerstein

See the full list of features within our NASGP membership plans